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Abstract
Background: A limited number of  antibiotics are recommended for the therapy of  Stenotrophomonas maltophilia infections 
due to therapy difficulties caused by its numerous mechanisms of  resistance.
Objectives: In this study conducted over a period of  approximately 5 years we aimed to determine resistance rates of  S. 
maltophilia based on drug classification recommended by Clinical and Laboratory Standards Institute.
Methods: A total of  118 S. maltophilia strains isolated from various clinical specimens between January 2006 and June 2012 
were included in the study. BD Phoenixautomated microbiology system (Becton Dickinson, USA) was utilized for species 
level identification and antibiotic susceptibility testing.
Results: Sixty seven of  S. maltophilia strains were isolated from tracheal aspirate isolates, 17 from blood, 10 from sputum, 
10 from wound and 14 from other clinical specimens. Levofloxacin was found to be the most effective antibiotic against 
S. maltophilia strains with resistance rate of  7.6%. The resistance rates to other antibiotics were as follows: chloramphenicol 
18.2%, trimethoprim-sulfamethoxazole 20.3% and ceftazidime 72%.
Conclusion: The study revealed that S. maltophilia is resistant to many antibiotics. The treatment of  infections caused by S. 
maltophilia should be preferred primarily as levofloxacin, chloramphenicol, and TMP-SXT, respectively.
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Introduction
Stenotrophomonas maltophilia is a resistant pathogen that 
can cause bacteremia, endocarditis, respiratory system, 
central nervous system and urinary tract infections in 
patients with risk factors like malignancy or neutrope-
nia, use of  broad-spectrum antibiotics like carbapenem 
or long-term hospitalization1,2.
Outside of  hospital, S. maltophilia can be found in wa-
ter resources like rivers, lakes and wells, as well as in 
soil and various plants. In hospital, these bacteria can 
be isolated from central venous/arterial monitors, di-
alysis machines, disinfectant solutions, deionized water, 
nebulizers, ventilation systems and hands of  health care 
personnel. Although S. maltophilia can be isolated from 
wet environments, its long term survival in a dry envi-
ronment is not very common3,4. S. maltophilia possesses 
virulence factors including DNase, RNase, fibrinolysin, 
lipases, hyaluronidase, protease, and elastase. These 
bacteria have the ability to survive in medical soutions 
and adhere to the prosthetic material5.
S. maltophilia can manifest resistance to many com-
monly used antibiotics, including carbapenems, which 
makes infections caused by this bacterium difficult to 
treat6. Inappropriate use of  broad-spectrum antibiotics 
like imipenem presents risk factor for S. maltophilia in-
fections. The most important reason for this is the abil-
ity of  S. maltophilia to hydrolyse imipenem7.
S. maltophilia strains are intrinsically resistant to multiple 
antibiotics due to aminoglycoside acetyl-transferase and 
enzymes that inactivate erythromycin and genes encod-
ing efflux pumps8. Besides the S. maltophilia strains be-
ing resistant to one antibiotic, these strains can develop 
resistance to multiple antibiotics (multidrug resistance). 
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Due to frequent and irrational use of  the broad-spec-
trum antibiotics, pan resistant strains have been occa-
sionally reported in the hospitals9. The aim of  this study 
was to determine resistance rates of S. maltophilia strains 
to the antibiotics specified by CLSI in the context of  





The present study was performed in the microbiology 
laboratory of  Yuzuncu Yil University School of  Medi-
cine, Van, Turkey. Our hospital is a 550-bed facility that 
provides health care to the city of  Van and neighboring 
provinces and thus serves as regional medical center. 
All together, it provides health care services to the ap-
proximately 2.5 million people.
Collection of  strains, bacterial identification and 
antibiotic susceptibility testing
A total of  118 S. maltophilia strains isolated from various 
clinical specimens between January 2006 and June 2012 
were included in the study. In the study, the resistance 
rates of  Stenotrophomonas strains were screened retro-
spectively. Received samples were inoculated onto 5% 
sheep blood agar and EMB agar and incubated for 24h 
at 37oC. Blood culture samples were analyzed using ful-
ly automated blood culture system BacT/Alert 3D (bi-
oMerieux, France). A quantitative sputum culture was 
performed and specimens yielding 105 CFU per ml and 
more were evaluated.  BD Phoenix automated micro-
biology system (Becton Dickinson, USA) was utilized 
for species level identification and antibiotic suscepti-
bility testing of  EMB agar lactose and cytochrome oxi-
dase negative, non-fermentative bacteria. The antibiotic 
classes for S. maltophilia strains recommended by CLSI 
were included in the study10. According to the CLSI, 
MIC interpretive criteria  of  antibiotic resistance for 
ceftazidime, trimethoprim-sulfametoxasole, chloram-
phenicol, and Levofloxacin were accepted as ≥32, ≥4 
PubMed /76, ≥32, and ≥8 (μg/mL), respectively.
Study design and statistical analysis
This study was conducted as a retrospective clinical 
study. Z test was used for evaluate the difference be-
tween antibiotic resistance rate. Level of  statistical sig-
nificance was considered to be 5% and MINITAB (ver: 
14) statistical package program was used for analysis.
 
Results
The distribution of  118 S. maltophilia strains according 
to clinics was as follows: 51%  Pediatrics, 17% Chest 
Diseases, 12%  Anesthesia -Intensive Care Unit (ICU), 
3% Otorhinolaryngology, 3% Internal Medicine, 3% 
Neurosurgery and 11% other clinics. Sixty seven of  
S. maltophilia strains were isolated from tracheal aspi-
rate isolates, 17 from blood, 10 from sputum, 10 from 
wound, 3 from ear, 2 from CSF, 2 from paracentesis, 2 
from pleural fluid, 2 from urine, 2 from puncture flu-
id and 1 from catheter. The most effective antibiotic 
against S. maltophilia strains was levofloxacin. The resist-
ance rates of  isolated S. maltophilia strains to antibiotics 
recommended by CLSI are shown in Table. Although 
the difference between trimethoprim-sulfametnoxazole 
and chloramphenicol has not been found statistically 
significant, the differences between other antibiotics 
have been found to be statistically significant (p<0.05).
Table. The resistance rates of S.maltophilia strains to selected antibiotics (%) 
 
Antibiotic Class* n R Resistance rate (%) 
Ceftazidime B 118 85 72 
TMP-SXT A 118 24 20,3 
Chloramphenicol B 88 16 18,2 
Levofloxacin B 115 9 7,6 
*: Drug classes specified in CLSI 2010 guidelines (A: routinely reported drugs, B: 
important drugs and drugs that should be tested with priority)  
n: Number of tested strains, R: Number of resistant strains, 
TMP-SXT: Trimethoprim-sulfametoxasole 
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Discussion
In recent years non fermentative Gram negative bacte-
ria (Pseudomonas aeruginosa, Acinetobacter baumannii, Steno-
trophomonas maltophilia ve Burkholderia cepacia) have been 
increasingly recognized as an important cause of  no-
socomial infections. Many difficulties are encountered 
in the treatment of  these infections due to multiple 
antibiotic resistance of  these bacteria10,11. S. maltophilia 
related nosocomial infections occur more frequently 
in immunocompromised patients and patients on me-
chanic ventilation in ICU and these infections are usu-
ally associated with high morbidity and mortality rates12.
Natural resistance of  S. maltophilia to multiple antibiot-
ics used against Gram-negative bacteria increases mor-
tality rates in all S. maltophilia infections, especially in 
bacteremia. Araoka et al13 reported mortality rate higher 
than 50% in the patients with S. maltophilia related bac-
teremia.
In the previous studies S. maltophilia has been isolat-
ed mainly from respiratory (49%) and blood samples 
(41%). In our country, similarly, the most common clin-
ical material for isolation of S. maltophilia consists of  
respiratory and blood samples. Celebi et al14 reported 
that this bacterium was mainly isolated from respirato-
ry (67%) and blood (16%) samples. In accordance with 
literature, respiratory (65%) and blood (14%) samples 
were the most common clinical material for the isola-
tion of  S. maltophilia in the present study as well. 
S. maltophilia strains isolated from the sample according 
to the diagnostic criteria were admitted to the respira-
tory pathogen.
Limited therapy options are available for the treatment 
of  infections associated with S. maltophilia strains due 
to their natural resistance to many antibiotics like be-
ta-lactam antibiotics or aminoglycosides15. According 
to in vitro studies, the most effective antibiotics for S. 
maltophilia strains are levofloxacin and TMP-SXT. In 
a study of  Hankiewicz et al16 conducted with 80 clin-
ical isolates of  S. maltophilia strains of  which 60% were 
multiple resistant, resistance rates for levofloxacin and 
TMP-SXT were found to be 4% and 29%, respectively 
. Sader et al17 reported resistance to levofloxacin as 7% 
and resistance to SXT as 5%. In our country, Turk Dagi 
et al18 worked with S. maltophilia strains isolated from 
blood culture and determined resistance rates of  levo-
floxacin and TMP-SXT as 20% and 10%, respectively. 
On the other hand, Dizbay et al19 reported resistance 
to TMP-SXT as 22% in a sample of  89 nosocomial 
S.maltophilia strains. In the present study resistance rate 
to levofloxacin and TMP-SXT were 7.6% and 20.3% 
respectively, which is in accordance with previous stud-
ies. Some researchers have argued that despite low re-
sistance rate of  TMP-SXT it should be used in combi-
nation with some other antimicrobial agent due to its 
low efficacy when used alone16.
Chloramphenicol has been reported by several stud-
ies as a highly efficient antibiotic against S. maltophil-
ia strains. In a study of  Niks et al20, chloramphenicol 
resistance was 23% in multiresistant hospital bacterial 
pathogens. Nicodemo et al21 compared three different 
methods and reported chloramphenicol resistance be-
tween 19 and 23%. Although data on chloramphenicol 
resistance in our country was insufficient, in the present 
study resistance rate to chloramphenicol was found to 
be 18%. Despite its low resistance rate chloramphenicol 
is not widely used in clinical practice due to its poten-
tial side effects like bone marrow suppression or plastic 
anemia22.
Resistance of  S. maltophilia strains to ceftazidime vary. 
In a study from Europe of  Masgala et al23 ceftazidime 
resistance was reported as 24%. On the other hand, re-
sistance rates to ceftazidime reported in our country are 
considerable higher. In the studies conducted in Turkey, 
Dizbay et al19 found ceftazidime resistance rate to be 
45%, TurkDagi et al18 78% and Zer et al6 88%. Results 
regarding ceftazidime resistance rate obtained in this 
study (72%) are in accordance with national data.
Carbapenems are widely used antibiotics for empirical 
treatment of  infections with Gram negative bacteria in 
hospital and especially in intensive care units. This caus-
es treatment delay and leads to the rise of  infections 
related to opportunistic pathogens like S. maltophilia 
which is naturally resistant to carbapenems. For this 
reason, pathogens resistant to multiple commonly used 
antibiotics, with high transmissibility in ICU and with 
problematic diagnosis and treatment like S. maltophilia 
should be considered as cause of  infection in long-stay 
patients, patients with malignancy or neutropenia and 
patients using broad-spectrum antibiotics like carbap-
enem.
Limitation
Firstly, the study was conducted retrospectively. Sec-
ondly, study was carried out in one center only. Multi-
center study should be done with more strains.
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Conclusion
The study revealed that S. maltophilia is resistant to 
many antibiotics. The treatment of  infections caused 
by S. maltophilia should be preferred primarily as lev-
ofloxacin,chloramphenicol,and TMP-SXT, respectively. 
Additionally, treatment planning in accordance with in 
vitro susceptibility test results are required for efficient 
treatment of  S.maltophilia infections.
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